Dementia and Alzheimer Disease

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

The Director of Cleveland Clinic Lou Ruvo Center for Brain Health spoke about the rapidly changing landscape of treatments for Alzheimer disease.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Neurology News Network for the week of September 22, 2018.

The accuracy and potential utility of the [18F]flortaucipir tracer in patient care will require further research in clinically more representative populations.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.

Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

A meta-analysis of 16 studies looked at the association between apathy in older individuals with and without incident dementia.

Memory decline was worse for patients with MCI receiving supportive therapy over behavioral activation.

An emerging class of cancer drugs may help treat brain disorders such as amyotrophic lateral sclerosis frontotemporal dementia.

A meta-analysis revealed a history of stroke increases dementia risk by around 70%, and recent strokes more than doubled the risk.

If granted approval, DTHR-ALZ would be the first non-pharmacological prescription treatment to mitigate agitation and depression associated with Alzheimer disease.

Advances in technology are broadening treatment options for patients with major neurocognitive dysfunction.

Results concluded that noninvasive OCT was able to detect significant thinning especially in the center of the retina, around the fovea, in the inner layers of the retina prior to any evidence of dementia.

After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.

Lutz Frölich, MD, PhD, provides a look at BI409306, a novel selective PDE9A inhibitor, and how the negative results of its phase II trial can inform the community.

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

Patients treated with fludrocortisone normalized their serum sodium levels in only 4 days—significantly quicker than saline alone, which took 15 days.

Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.